Vaidya Sane

The transcript provided does not mention any information regarding the current or expected order book or pending orders for Vaidya Sane Ayurved Laboratories Limited. The discussion primarily covers topics related to hospital expansion, marketing strategies, financials, acquisitions, clinic and hospital business models, and growth projections but does not provide specific details on order books or pending orders.

- The company plans to utilize money raised from warrants in the next one year, which can partly be used to pay off short-term debt. - Fund utilization will also focus on various initiatives beyond just debt repayment, including hospital expansion and operational improvements. - There is no explicit mention of fresh fundraising through new debt or equity in the immediate future within the provided excerpts. - Existing short-term borrowings have increased due to acquisitions and inter-company transactions, but no new fundraising rounds were detailed. - Focus appears to be on constructive utilization of current cash reserves and funds raised via warrants to support growth and reduce debt.

- Plans to invest in hospital expansion, specifically the Mumbai Khopoli Hospital: - Current bed capacity: 53 beds. - Future plan: Addition of 100 more beds within next 12 to 18 months, pending approval from MSRDC. - Investment to improve hospital accommodation once approval is received. - Acquisitions made: - UV Ayurgen (for in-house manufacturing of food products) to reduce purchase costs by 20%-30%. - Dynamic Remedies Private Limited (to manufacture medicines) to improve margins and product quality. - Expansion plans include opening franchise hospitals where expenses are borne by franchisees but revenue shares accrue to the company. - Marketing investment planned: Increasing marketing budget from Rs. 14-15 crores to Rs. 18-20 crores to boost top-line growth.

- The company targets a 15% to 20% growth in topline (revenue) in the coming year. - Expansion focus will be on hospitals, with plans to increase existing hospital capacity, which typically yield higher EBITDA margins than clinics. - Clinic expansion will continue primarily through franchise models, reducing company investment and maintaining presence in local residential areas. - Marketing budget is planned to increase from Rs. 14-15 crores to Rs. 18-20 crores to boost topline and attract more diseased patients. - The new marketing strategy aims to target diseased patients (diabetes, heart conditions) for higher ticket sizes and improved revenue. - Expect operational breakeven for new hospitals like Vizag within 6-7 months of opening. - Long-term clinic expansion to 1000 clinics delayed to 3-4 years timeframe, with a combination of online and offline presence expected. - Overall, sustainable EBITDA margins targeted between 15% and 20% driven by optimized cost structure and revenue growth.

- The company targets a topline growth of approximately 15% to 20% in the coming year (FY25). - Sustainable EBITDA margins are expected to improve from a conservative 10% to a target range of 15% to 20% over the next 3-5 years, with current efforts already underway to reduce expenses. - Employee cost reductions and other cost control measures implemented will contribute to EBITDA margin improvement. - Marketing expenses are planned to increase from around Rs. 14-15 crores to Rs. 18-20 crores to drive topline growth. - Profit after tax weakened to Rs. 1.99 crores in FY24 but is expected to improve with revenue growth and margin expansion efforts. - EPS was Rs. 1.88 in FY24, with growth expected alongside improved profitability. - Expansion focus will be on hospital business, which has higher margins (20-30% EBITDA) compared to clinics (30-40% unallocated margins), supporting margin growth.